A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma (Q33829132)

29 July 2017

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma (English)

1 reference

29 July 2017

1 reference

1 reference

3

Ruben Niesvizky

1 reference

29 July 2017

Mohamad Hussein

1

1 reference

29 July 2017

James R Berenson

2

1 reference

29 July 2017

Nikhil Munshi

4

1 reference

29 July 2017

Jeffrey Matous

5

1 reference

29 July 2017

Ronald Sobecks

6

1 reference

29 July 2017

Kate Harrop

7

1 reference

29 July 2017

Jonathan G Drachman

8

1 reference

29 July 2017

Nancy Whiting

9

1 reference

29 July 2017

language of work or name

1 reference

4 February 2010

1 reference

29 July 2017

1 reference

29 July 2017

95

1 reference

29 July 2017

5

1 reference

29 July 2017

845-848

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

29 July 2017

1 reference

4 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Improved survival in multiple myeloma and the impact of novel therapies

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Global cancer statistics, 2002

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Prospects for CD40-directed experimental therapy of human cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864394

Myeloma therapy: 25 years forward--immune modulation then and now

4 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20133895

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2009.008003

1 reference

29 July 2017

1 reference

29 July 2017

1 reference